BioSpace News Archive

Atrion Corporation announced that for the fourth quarter of 2019 revenues were $34.5 million compared to $34.9 million in the same period of 2018, net income was $8.1 million compared to $7.7 million in the prior year period, and diluted earnings per share were $4.33 compared to $4.17 in the prior-year period.

Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today highlighted the publication of an article describing the anti-epileptic and anti-convulsive activity of betahistine in a mouse model.

Biomerica Inc. announced that the Company completed a private placement of $2 million of convertible preferred stock with Palm Global Small Cap Master Fund LP.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $1.55 per share on its outstanding shares of Common Stock.

Johnson & Johnson will participate in the Barclays Global Healthcare Conference on Wednesday, March 11th, at the Loews Miami Beach Hotel, Miami Beach, FL. Ciro Romer, Company Group Chairman, Medical Devices North America will represent the Company in a session scheduled at 10:15 a.m.

SPEAR Physical & Occupational Therapy is excited to announce the addition of Zach Borg to its team as its Chief Development Officer.

CEL-SCI Corporation issued a letter to its shareholders. This letter will be sent to the Company’s shareholders along with the proxy to the upcoming annual meeting.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the fourth quarter and full-year ended December 31, 2019.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today financial results for the three-months and full-year ended December 31, 2019 and reaffirmed revenue guidance for 2020.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, reported financial results for the three and twelve months ended December 31, 2019.